18F-FSPG PET/CT for Cancer Patients on Therapy

Andrei Iagaru7 enrolled

Overview

The goal of this phase 2 study trial is to evaluate the utility of the radiolabel 18F-FSPG used before and after treatment to diagnose, predict, and evaluate response to therapy in patients with a wide variety of metastatic cancers.

OUTLINE: Patients are evaluated with a PET/CT scan using the radiolabel 18F-FSPG \[18F-(S)-4-(3-fluoropropyl)-L-glutamic acid\] or 18F-FDG (\[18F\]-fluorodeoxyglucose), before and after therapeutic treatment. PRIMARY OBJECTIVE: Uptake of the radiolabel 18F-FSPG in patients with biopsy-proven cancer will be evaluated and compared to the uptake of 18F-FDG, before and after therapy (non-specified) in the same group of patients. SECONDARY OBJECTIVES: * Compare the agreement of the clinical assessment for cancer status between 18F-FSPG and 18F-FDG. * Safety and tolerability of 18F-FSPG and 18F-FDG.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

B-Cell Neoplasm Estrogen Receptor Negative HER2/Neu Negative

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Written informed consent * Able to complete a PET/CT scan without the use of sedation * Females: * Of childbearing potential must: * Not be nursing * Have a negative serum pregnancy test documented within 48 hours prior to administration of 18F FSPG PET/CT * Not of childbearing potential must be: * Physiologically postmenopausal (cessation of menses for more than 1 year) * Surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy) * Histologically confirmed cancer that is advanced; metastatic; or otherwise not suitable for surgical resection with curative intent * Scheduled to begin therapy * The time interval between 18F FSPG PET/CT and standard of care imaging (ie, 18F FDG PET/CT, diagnostic CT, or MRI) should be within 4 weeks (exceptions will be allowed for 6 weeks, if there are no other options) * Ideally, there should be no chemotherapy, radiotherapy, or immune/biologic therapy or biopsy between other imaging (PET/CTs, MRI, or diagnostic CTs) and 18F FSPG PET/CT scheduled or performed (exceptions by investigator discretion) * No clinically relevant deviations in renal function (serum creatinine \> grade 2 Common Terminology Criteria for Adverse Events \[CTCAE\] version 4.0); maximal interval between confirmation of renal function and injection of 18F FSPG is 1 week Exclusion Criteria: * Scheduled for surgery and/or another invasive procedure (except biopsy) within the time period of 1 month prior to 18F FSPG administration * Known sensitivity to 18F FSPG or components of the preparation * Investigator precludes participation for scientific reasons, for reasons of compliance, or for reasons of the patient's safety

Outcomes

Primary Outcomes

Change From Baseline in Standard Uptake Value Maximum (SUVmax) Post-treatment

Standard Uptake Values (SUVs) for the radiotracers labels 18F-FSPG and 18F-FDG were assessed in tumor tissues of study participants, before (baseline), and after therapeutic treatment. Time frame was specified by protocol as at baseline, and at the time of clinical assessments during individual patient regular medical care. The time of the post-treatment assessment was not otherwise explicitly defined but could be anytime within 2 years. The outcome is reported as the difference of means from baseline to post-treatment (a number without dispersion), for all lesions for which an SUVmax value was assessed. A negative result indicates less uptake of radiotracer suggesting a small volume of tumor.

Time frame: Baseline and up to 2 years

Secondary Outcomes

Number of Treatment-Related Adverse Events

Safety and tolerability of 18F-FSPG and 18F-FDG were assessed as treatment-related adverse events, and reported as the number of events related to each treatment, without dispersion.

Time frame: Baseline to up to 2 years

Change From Baseline in Lesion Size Post-treatment, by 18F-FSPG or 18F-FDGs

Lesion size in centimeters (cm) were assessed in 2 dimensions from the computed tomography (CT) component of PET/CT and the area in cm2 calculated for lesion locations at baseline and after treatment. Time frame was specified by protocol as at baseline, and at the time of clinical assessments during individual patient regular medical care. The time of the post-treatment assessment was not otherwise explicitly defined but could be anytime within 2 years. The outcome is reported the difference in area in cm² for each lesion (a number without dispersion).